Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silibinin + Daunorubicin/Idarubicin in Newly Diagnosed AML (Non-M3)
NCT07561892Phase 4Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of silibinin in acute myeloid leukemia (AML), sponsored by Fujian Medical University Union Hospital. Started Apr 2022; status: recruiting.
02
Drugs
silibinin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07561892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561892.